165 related articles for article (PubMed ID: 2774511)
1. Peripheral pharmacokinetics of apomorphine in humans.
Gancher ST; Woodward WR; Boucher B; Nutt JG
Ann Neurol; 1989 Aug; 26(2):232-8. PubMed ID: 2774511
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of apomorphine in Parkinson's disease.
Gancher S
J Neural Transm Suppl; 1995; 45():137-41. PubMed ID: 8748619
[TBL] [Abstract][Full Text] [Related]
3. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
Gancher ST; Woodward WR; Gliessman P; Boucher B; Nutt JG
Ann Neurol; 1990 Jun; 27(6):660-5. PubMed ID: 2360803
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
6. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
Harder S; Baas H; Demisch L; Simon E
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):355-62. PubMed ID: 9707348
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses.
Hofstee DJ; Neef C; van Laar T; Jansen EN
Clin Neuropharmacol; 1994 Feb; 17(1):45-52. PubMed ID: 8149359
[TBL] [Abstract][Full Text] [Related]
9. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of apomorphine in parkinsonian patients.
Nicolle E; Pollak P; Serre-Debeauvais F; Richard P; Gervason CL; Broussolle E; Gavend M
Fundam Clin Pharmacol; 1993; 7(5):245-52. PubMed ID: 8370571
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
[TBL] [Abstract][Full Text] [Related]
13. Absorption of apomorphine by various routes in parkinsonism.
Gancher ST; Nutt JG; Woodward WR
Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
[TBL] [Abstract][Full Text] [Related]
14. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
[TBL] [Abstract][Full Text] [Related]
15. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
18. Intravenous versus subcutaneous injections of apomorphine in rabbits: a pharmacokinetic paradox.
Ugwoke MI; Agu RU; Kinget R; Verbeke N
Boll Chim Farm; 2003 Oct; 142(8):315-8. PubMed ID: 15040458
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
20. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.
Gancher ST; Nutt JG; Woodward WR
Mov Disord; 1995 Jan; 10(1):37-43. PubMed ID: 7885354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
